PDS Biotechnology Corp
PDSB0.715USD
+0.025+3.59%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
34.11MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über PDS Biotechnology Corp Unternehmen
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
PDS Biotechnology Corp Informationen
BörsenkürzelPDSB
Name des UnternehmensPDS Biotechnology Corp
IPO-datumOct 01, 2015
CEOBedu-Addo (Frank)
Anzahl der mitarbeiter24
WertpapierartOrdinary Share
GeschäftsjahresendeOct 01
Addresse303A College Road East
StadtPRINCETON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl08540
Telefon18002083343
Websitehttps://www.pdsbiotech.com
BörsenkürzelPDSB
IPO-datumOct 01, 2015
CEOBedu-Addo (Frank)
Führungskräfte von PDS Biotechnology Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Gregory L. Conn, Ph.D.
Dr. Gregory L. Conn, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
--
--
Mr. Spencer Brown
Mr. Spencer Brown
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. Lars Boesgaard
Mr. Lars Boesgaard
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
--
--
Dr. Kirk V. Shepard, M.D.
Dr. Kirk V. Shepard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Gregory L. Conn, Ph.D.
Dr. Gregory L. Conn, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
3.73%
Bedu-Addo (Frank)
1.32%
BlackRock Institutional Trust Company, N.A.
0.97%
Geode Capital Management, L.L.C.
0.92%
Sykes (Richard)
0.85%
Andere
92.22%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
3.73%
Bedu-Addo (Frank)
1.32%
BlackRock Institutional Trust Company, N.A.
0.97%
Geode Capital Management, L.L.C.
0.92%
Sykes (Richard)
0.85%
Andere
92.22%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
6.56%
Individual Investor
2.69%
Investment Advisor/Hedge Fund
2.12%
Hedge Fund
1.29%
Research Firm
0.65%
Venture Capital
0.04%
Andere
86.65%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
172
5.60M
10.70%
-4.10M
2025Q3
178
7.65M
16.41%
-3.65M
2025Q2
188
9.63M
21.07%
+1.19M
2025Q1
201
9.77M
22.08%
+1.54M
2024Q4
205
5.67M
12.73%
-3.40M
2024Q3
205
5.76M
15.58%
-3.85M
2024Q2
208
6.94M
18.83%
-4.50M
2024Q1
195
8.96M
25.12%
-3.13M
2023Q4
194
9.68M
31.15%
-1.91M
2023Q3
192
9.20M
29.70%
-3.29M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
1.90M
3.63%
-49.90K
-2.56%
Sep 30, 2025
Bedu-Addo (Frank)
690.87K
1.32%
--
--
Apr 17, 2025
BlackRock Institutional Trust Company, N.A.
508.21K
0.97%
+3.13K
+0.62%
Sep 30, 2025
Geode Capital Management, L.L.C.
482.00K
0.92%
+64.06K
+15.33%
Sep 30, 2025
Sykes (Richard)
445.11K
0.85%
--
--
Apr 17, 2025
Citadel Advisors LLC
386.43K
0.74%
+137.41K
+55.18%
Sep 30, 2025
Squarepoint Capital LLP
291.63K
0.56%
+193.86K
+198.29%
Sep 30, 2025
Renaissance Technologies LLC
275.86K
0.53%
+170.17K
+161.02%
Sep 30, 2025
UBS Financial Services, Inc.
86.26K
0.16%
-337.96K
-79.67%
Sep 30, 2025
William Blair & Company, L.L.C. (Research)
250.00K
0.48%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Avantis US Small Cap Equity ETF
0%
Global X Russell 2000 Covered Call ETF
0%
ProShares UltraPro Russell2000
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Mehr Anzeigen
iShares Micro-Cap ETF
Anteil0.01%
DFA Dimensional US Sustainability Core 1 ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
Global X Russell 2000 Covered Call ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
Invesco NASDAQ Future Gen 200 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
